Ghent University Academic Bibliography

Advanced

Raltitrexed in mesothelioma

VEERLE SURMONT UGent and Jan Van Meerbeeck UGent (2011) EXPERT REVIEW OF ANTICANCER THERAPY. 11(10). p.1481-1490
abstract
Raltitrexed is a cytotoxic agent, rationally designed to inhibit a specific molecular target, thymidylate synthase. In contrast to other agents, raltitrexed inhibits thymidylate synthase directly and specifically in a mixed, noncompetitive manner, which may lead to an improved toxicity profile. After promising Phase II trials exploring the activity of raltitrexed either as a single agent or in combination with a platinum agent, a Phase III randomized study demonstrated that the combination of raltitrexed and cisplatin improves overall survival in malignant pleural mesothelioma (MPM) and is superior compared with cisplatin alone, without harmful effect on health-related quality of life. Moreover, the cost-effectiveness analysis found raltitrexed plus cisplatin to be cost effective compared with cisplatin and compared with active supportive care. Based on these results, raltitrexed is registered for the treatment of MPM in several European countries. MPM is hard to treat and has a poor prognosis. New treatment options, such as a combination of cisplatin and raltitrexed, which improve patient outcomes with no detrimental effect on quality of life, are a welcome addition to our therapeutic portfolio.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
TS inhibitor, ZD1694, Tomudex (R), raltitrexed, quality of life, mesothelioma, MALIGNANT-PLEURAL-MESOTHELIOMA, THYMIDYLATE SYNTHASE INHIBITOR, PHASE-II TRIAL, NATIONAL-CANCER-INSTITUTE, CELL LUNG-CANCER, QUINAZOLINE ANTIFOLATE, ICI D1694, COLORECTAL-CANCER, CHEMOTHERAPY, CISPLATIN
journal title
EXPERT REVIEW OF ANTICANCER THERAPY
Expert Rev. Anticancer Ther
volume
11
issue
10
pages
1481 - 1490
Web of Science type
Review
Web of Science id
000296856800006
JCR category
ONCOLOGY
JCR impact factor
2.652 (2011)
JCR rank
88/190 (2011)
JCR quartile
2 (2011)
ISSN
1473-7140
DOI
10.1586/ERA.11.136
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2044515
handle
http://hdl.handle.net/1854/LU-2044515
date created
2012-02-24 15:38:05
date last changed
2012-02-28 10:13:22
@article{2044515,
  abstract     = {Raltitrexed is a cytotoxic agent, rationally designed to inhibit a specific molecular target, thymidylate synthase. In contrast to other agents, raltitrexed inhibits thymidylate synthase directly and specifically in a mixed, noncompetitive manner, which may lead to an improved toxicity profile. After promising Phase II trials exploring the activity of raltitrexed either as a single agent or in combination with a platinum agent, a Phase III randomized study demonstrated that the combination of raltitrexed and cisplatin improves overall survival in malignant pleural mesothelioma (MPM) and is superior compared with cisplatin alone, without harmful effect on health-related quality of life. Moreover, the cost-effectiveness analysis found raltitrexed plus cisplatin to be cost effective compared with cisplatin and compared with active supportive care. Based on these results, raltitrexed is registered for the treatment of MPM in several European countries. MPM is hard to treat and has a poor prognosis. New treatment options, such as a combination of cisplatin and raltitrexed, which improve patient outcomes with no detrimental effect on quality of life, are a welcome addition to our therapeutic portfolio.},
  author       = {SURMONT, VEERLE and Van Meerbeeck, Jan},
  issn         = {1473-7140},
  journal      = {EXPERT REVIEW OF ANTICANCER THERAPY},
  keyword      = {TS inhibitor,ZD1694,Tomudex (R),raltitrexed,quality of life,mesothelioma,MALIGNANT-PLEURAL-MESOTHELIOMA,THYMIDYLATE SYNTHASE INHIBITOR,PHASE-II TRIAL,NATIONAL-CANCER-INSTITUTE,CELL LUNG-CANCER,QUINAZOLINE ANTIFOLATE,ICI D1694,COLORECTAL-CANCER,CHEMOTHERAPY,CISPLATIN},
  language     = {eng},
  number       = {10},
  pages        = {1481--1490},
  title        = {Raltitrexed in mesothelioma},
  url          = {http://dx.doi.org/10.1586/ERA.11.136},
  volume       = {11},
  year         = {2011},
}

Chicago
SURMONT, VEERLE, and Jan Van Meerbeeck. 2011. “Raltitrexed in Mesothelioma.” Expert Review of Anticancer Therapy 11 (10): 1481–1490.
APA
SURMONT, VEERLE, & Van Meerbeeck, J. (2011). Raltitrexed in mesothelioma. EXPERT REVIEW OF ANTICANCER THERAPY, 11(10), 1481–1490.
Vancouver
1.
SURMONT V, Van Meerbeeck J. Raltitrexed in mesothelioma. EXPERT REVIEW OF ANTICANCER THERAPY. 2011;11(10):1481–90.
MLA
SURMONT, VEERLE, and Jan Van Meerbeeck. “Raltitrexed in Mesothelioma.” EXPERT REVIEW OF ANTICANCER THERAPY 11.10 (2011): 1481–1490. Print.